The human mannose-binding protein (MBP) is a pattern recognition molecule that appears to play a role in initial host defence. MBP activates the complement cascade and it may act as an opsonin both in the absence and in the presence of complement. A number of distinct MBP allelic forms exist in different population groups. An allele that occurs in 5-7% of Caucasians was identified by an inability to activate the complement system. A homozygous mutation at base pair 230 of the MBP gene results in a Gly-to-Asp substitution at the fifth collagen repeat. It 
INTRODUCTION
Serum mannose-binding protein (MBP) is a C-type lectin [1] which recognizes the patterns of oligosaccharides that decorate yeast, certain Gram-negative and -positive bacteria, the envelope glycoprotein of the human immunodeficiency virus, and the haemagglutinin of some strains of influenza virus. MBP appears to play an important role in the first line of host defence against a broad range of pathogens. MBP is considered to be a member of the collectins, a group of proteins that contain a collagen region as well as globular, lectin-like heads [2, 3] . The MBP may act as an opsonin [4] through binding to the collectin receptor (Clq receptor) on phagocytes. In addition, when bound to its ligand in vitro, MBP can destroy bacteria directly by activating the complement cascade [5] [6] [7] . Previous reports suggested that MBP initiates complement activation by binding the Clr2Cls2 complex and generating active Cls [8, 9] . However, we have demonstrated that human serum MBP can associate with a CIslike serine protease, designated MASP (MBP-associated serine protease), that activates the complement cascade by consuming C4 and C2 [10] . Thus complement activation via the formation of an MBP-MASP complex (termed the lectin pathway) represents a new mechanism for regulating this cascade [11] .
It has been reported that low to absent baseline levels of serum MBP may be associated with a complement-dependent opsonic defect that results in recurrent infections in infants [12] . These patients have an MBP allele in which guanine is replaced by adenine at base 230. This base pair substitution results in an aspartic acid residue instead of a glycine at the fifth collagen repeat [13] . Although this substitution was predicted to disrupt the collagen helix leading to dysfunctional MBP, studies with recombinant MBPs have shown that both recombinant (r)MBPG the MBP-associated serine protease (MASP), has been described. MBP-MASP complexes circulate in serum and result in the direct activation of a novel complement pathway (lectin pathway) in the absence of the first complement components. In this study we demonstrate that MASP and its proenzyme proMASP are unable to bind to recombinant (r)MBPD. This lack of a MASP-rMBPD association corresponds to a failure of the Gly-54-+Asp form of MBP to activate complement. Our results provide a biochemical basis for the functional deficit in the Gly-54-. Asp allelic form of MBP and suggest that the proMASP/ MASP binding site maps to the fifth collagen repeat of MBP.
(wild-type) and rMBPD (Gly-54 -* Asp form) assemble into multimers and exhibit opsonic activities [14] . Unlike recombinant MBPG, however, recombinant MBPD is unable to initiate complement activation as determined by C4 activation in human serum. In this paper we report the molecular basis of the failure of complement activation by recombinant MBPD.
MATERIALS AND METHODS Reagents
Mannan from Saccharomyces cerevisiae was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Human serum MBP, MASP [10] , recombinant MBPs (rMBPG and rMBPD) [14] , and human C4 [15] , C2 [16] and oxidized C2 [17] were prepared as described previously. Human MASP proenzyme (proMASP) was purified using the purification method for MASP [10] , with modifications. Briefly, human serum was chromatographed on mannan-Sepharose followed by anti-MBP-Sepharose in the presence ofp-nitrophenyl p-guanidinobenzoate to prevent autoactivation of proMASP. Veronal buffered saline (VB) was a standard solution of Veronal buffer containing 0.148 M NaCl (pH 7.4). EDTA-GVB was VB supplemented with 10 mM EDTA and 0.1 % gelatin. MGVB was low-ionic-strength VB containing 0.1 % gelatin, 2.3 % mannitol, 2 mM CaCl2 and 0.5 mM MgCl2. Na125I was purchased from Amersham International.
Haemolytic assay The C4-and C2-activating capacities of MASP and MBP on mannan were assayed as described previously [10] . Briefly, 100 #I ofmannan-coated sheep erythrocytes (Emannan; 108/ml of MGVB)
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was incubated with 50 ,1 of MASP or proMASP and 50 ,1u of MBP at 30°C for 30 min. After washing, the cells were suspended in MGVB at 108/ml and incubated with 50 ,ul of C4 and 50 ,ul of oxidized C2 at 30°C for 20 min, and then with 200 ,ul of guinea pig serum diluted with EDTA-GVB at 37°C for 1 h. After incubation, 1 ml of EDTA-GVB was added to the reaction mixtures and they were centrifuged. The haemolytic rate (y) was determined spectrophotometrically. The average number of haemolytic sites per cell (z) was calculated as z = -ln(I -y).
Binding of 1251-MASP to MBP on mannan MASP and MBPs were labelled using Na125I and lodo-Gen from Pierce Chemical Co., Rockford, IL, U. 
RESULTS AND DISCUSSION
In an earlier study we had described an MBP genotype in which glycine is substituted by aspartic acid at codon 54; this encoded a functional recombinant protein, rMBPD [14] . Like rMBPG, rMBPD is able to bind micro-organisms with similar avidity and act as an opsonin, but unlike rMBPG, rMBPD lacks the ability to activate complement. Thus we set out to determine whether the failure of rMBPD to activate C4 and C2 could be related to a defect in its ability to associate with MASP. First, we wished to establish that rMBPG, like serum MBP, can bind to Emannan, associate with MASP and initiate C4 and C2 activation (monitored as complement-dependent haemolysis). As shown in Figure  1 , in the presence of MASP, C4 and C2 as well as C3 and the terminal complement components, rMBPG induced the dosedependent lysis of Emannan. The results obtained with rMBPG were similar to those obtained with MBP purified from serum. We next set out to determine whether rMBPD was able to mediate MASP-dependent complement lysis of Em,anan. Under identical conditions, however, rMBPD failed to mediate Emannan lysis at all concentrations tested (Figure la) .
In the experiments shown in Figure l( [19] . In addition, Clq, the first complement component, has, like MBP collagen, tails that interact with Clr2Cls2, the functional equivalents of MASP [20] . Sellar et al. [21] have speculated that the aberration of a 'bend' in the regular collagen repeat that occurs in wild-type MBP and Clq is important for the binding of Clr2Cls2. Our results support the idea that MASP binds to MBP at the same site as these homologous serine proteases. We predict that the Gly-to-Asp substitution is likely to alter the phasing of the collagen helix, and this would allow for the disruption of the MASP binding site.
It is of interest that rMBPD retains its ability to act as an opsonin [14] . This indicates that the Gly-to-Asp change at the fifth collagen repeat does not disturb the interaction with the collectin receptor. In fact, according to a scheme proposed by Sim and colleagues, the addition of a positively charged amino acid at this position may be expected to enhance binding to the collectin receptor [22] . Their 
